Bauer F, Schulz P, Reber G, Bouvier C A
Thromb Haemost. 1983 Oct 31;50(3):652-5.
Three mucopolysaccharides (MPS) used in the treatment of degenerative joint disease were compared to heparin to establish their relative potencies on 3 coagulation tests, the aPTT, the antifactor Xa activity and the dilute thrombin time. One of the compounds, Arteparon, was one fourth as potent as heparin on the aPTT, but had little or no influence on the 2 other tests. Further in vitro studies suggested that Arteparon acted at a higher level than factor Xa generation in the intrinsic amplification system and that its effect was independent of antithrombin III. In vivo administration of Arteparon confirmed its anticoagulant properties, which raises the question of the clinical use of this MPS.
将用于治疗退行性关节疾病的三种黏多糖（MPS）与肝素进行比较，以确定它们在三种凝血试验（活化部分凝血活酶时间（aPTT）、抗Xa因子活性和稀释凝血酶时间）中的相对效价。其中一种化合物Arteparon在aPTT试验中的效价仅为肝素的四分之一，但对其他两项试验几乎没有影响。进一步的体外研究表明，Arteparon在内源性放大系统中作用于高于Xa因子生成的水平，且其作用独立于抗凝血酶III。Arteparon的体内给药证实了其抗凝特性，这就引发了这种黏多糖临床应用的问题。
